Cipla Ltd.

Cipla is currently trading at Rs. 656.25, up by 6.20 points or 0.95% from its previous closing of Rs. 650.05 on the BSE.

The scrip opened at Rs. 655.30 and has touched a high and low of Rs. 662.40 and Rs. 655.10 respectively. So far 61076 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 546.00 on 05-Sep-2014.

Last one week high and low of the scrip stood at Rs. 688.75 and Rs. 640.35 respectively. The current market cap of the company is Rs. 52707.77 crore.

The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.30% and 26.60% respectively.

Cipla, one of India’s leading generic pharmaceutical companies has reportedly acquired the exclusive rights to market skin care products of Percos India. This deal may be worth an estimated Rs 90 crore. The company will market few fast growing brands like Vedaderm, Claz, Actipeel, Tryses and Glycoveda, which have collective sales of around Rs 10 crore.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.